Largest Life Science Venture Transactions in 2017

Genuity Science is a life science technology company that provides world-leading genomics and multi-omic analytics bolstered by an advanced artificial intelligence (AI) and machine learning (ML) platform to illuminate the underlying cause of cancer and other diseases. Genuity Science is based in Boston, Massachusetts.

Yunfeng Capital
Investor
Venture Capital Firm
Shanghai, China
www.yfc.cn

Temasek Holdings
Investor
Sovereign Wealth Fund
Singapore, Singapore
www.temasek.com.sg

ImCheck Therapeutics is a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel superfamily of immunomodulators. Its clinical-stage program, ICT01, has been advancing to late-stage trials, demonstrating a unique mechanism of action that modulates both innate and adaptive immunity. These “first-in-class” activating antibodies may deliver superior clinical outcomes compared to first-generation immunotherapy approaches, in particular in rational combinations with immune checkpoint inhibitors and immunomodulatory anti-cancer drugs. Imcheck Therapeutics was founded in 2015 and is based in Marseilles, France.

GIMV
Investor
Private Equity Firm
Antwerp, Belgium
www.gimv.com

Bpifrance Investissement
Investor
www.bpifrance.fr

Andera Partners
Investor
Private Equity Firm
Paris, France
www.anderapartners.com

EQT Life Sciences
Investor
Growth Capital Firm
Amsterdam, Netherlands
eqtgroup.com/private-capital/eqt-life-sciences

Organogenesis is a provider of regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products for advanced wound care, orthopedics and spine. Organogenesis was established in 1985 and is headquartered in Canton, Massachusetts.

Eastward Capital
Investor
Private Equity Firm
West Newton, Massachusetts
www.eastwardcp.com

InflaRx is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. The company is also developing additional molecules targeting chronic and inflammation-related diseases. InflaRx was founded in 2007 and is based in Jena, Germany.

Bain Capital Private Equity
Investor
Private Equity Firm
Boston, Massachusetts
www.baincapitalprivateequity.com

IsoPlexis is a life sciences company developing a diagnostic platform that identifies a wide range of patient immune responses at the cellular level. Its platform can assess safety and efficacy of therapeutics and monitor disease progression, enabling improved therapeutic development and informing physician decisions. IsoPlexis was founded in 2013 and is based in Branford, Connecticut.

Ironwood Capital
Investor
Growth Capital Firm
Avon, Connecticut
www.ironwoodcap.com

Advantage Capital Partners
Investor
Growth Capital Firm
New Orleans, Louisiana
www.advantagecap.com

Front Range Biosciences is an operator of an agricultural biotech company that specializes in tissue culture propagation of high-value crops at an industrial scale to improve consistency and efficiency for clone production. FRB also has an advanced breeding program for identifying and improving commercially relevant traits. Front Range Biosciences was founded in 2015 and is based in Boulder, Colorado.

Salveo Capital
Investor
Venture Capital Firm
Northbrook, Illinois
www.salveocapital.com

Biora Therapeutics is a clinical-stage biotechnology company developing oral therapeutic-delivery platforms for needle-free systemic delivery of large molecules and targeted therapy delivery in the gastrointestinal tract. Biora Therapeutics was founded in 2010 and is based in San Diego, California.

Athyrium Capital Management
Investor
Asset Manager
New York, New York
www.athyrium.com

Ginkgo Bioworks is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo Bioworks was established in 2008 and is based in Boston, Massachusetts.

General Atlantic
Investor
Growth Capital Firm
New York, New York
www.generalatlantic.com

Avalyn Pharma is a biopharmaceutical company developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe pulmonary diseases. Avalyn Pharma was founded in 2010 and is based in Boston, Massachusetts.

Andera Partners
Investor
Private Equity Firm
Paris, France
www.anderapartners.com

TPG
Investor
Private Equity Firm
Fort Worth, Texas
www.tpg.com

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com

Checkmate Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the activation of innate immunity to treat cancer. Checkmate Pharmaceuticals was formed in 2015 and is based in Cambridge, Massachusetts.

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com

Sojournix is a biotechnology company developing innovative medicines for women's health and endocrine disorders. Sojournix is based in Waltham, Massachusetts.

Frazier Healthcare Partners
Investor
Growth Capital Firm
Seattle, Washington
www.frazierhealthcare.com

Vaxcyte is a biopharmaceutical company dedicated to the delivery of best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. Vaxcyte was incorporated in 2013 and is headquartered in San Carlos, California.

Frazier Healthcare Partners
Investor
Growth Capital Firm
Seattle, Washington
www.frazierhealthcare.com

TPG
Investor
Private Equity Firm
Fort Worth, Texas
www.tpg.com

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company, focused on the development of a platform of novel therapeutic compounds for the treatment of a broad range of autoimmune diseases based upon complement immunotherapy. Uncontrolled complement activation can lead to a wide range of life-threatening or debilitating disorders. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. Apellis Pharmaceuticals was founded in 2009 and is headquartered in Waltham, Massachusetts.

Vivo Capital
Investor
Growth Capital Firm
Palo Alto, California
www.vivocapital.com

Eight Roads
Investor
Private Equity Firm
London, United Kingdom
www.eightroads.com

Harmony is a biopharmaceutical company developing and commercializing innovative drugs to address unmet needs for patients with sleep and CNS disorders. Harmony was founded in 2017 and is based in Plymouth Meeting, Pennsylvania.

Vivo Capital
Investor
Growth Capital Firm
Palo Alto, California
www.vivocapital.com

Aisling Capital
Investor
Private Equity Firm
New York, New York
www.aislingcapital.com

HBM Partners
Investor
Private Equity Firm
Zug, Switzerland
www.hbmpartners.com

Medeor Therapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients. Medeor Therapeutics was founded in 2012 and is based in San Mateo, California.

Vivo Capital
Investor
Growth Capital Firm
Palo Alto, California
www.vivocapital.com

Outpost Medicine is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of urologic and gastrointestinal disorders. Outpost Medicine was founded in 2016 and is based in Indianapolis, Indiana.

Vivo Capital
Investor
Growth Capital Firm
Palo Alto, California
www.vivocapital.com

Frazier Healthcare Partners
Investor
Growth Capital Firm
Seattle, Washington
www.frazierhealthcare.com

Adams Street Partners
Investor
Asset Manager
Chicago, Illinois
www.adamsstreetpartners.com